French biotech company, Valneva, has announced positive results from the Phase III trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
The Phase III, Cov-Compare trial recruited a total of 4,012 participants, aged 18 years and older, across 26 trial sites in the UK. The trial successfully met both co-primary endpoints: VLA2001 had superior antibody titer levels compared to the active comparator vaccine, AstraZeneca’s AZD1222, and it had a neutralising antibody seroconversion rate above 95%.
